http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 19 Sep 2025 16:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html <p align="justify">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary short form base shelf prospectus (the “<strong>Prospectus</strong>”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when needed, during the 25-month period that the Prospectus, once made final, remains effective (the “<strong>Effective Period</strong>”). A copy of the http://www.streetinsider.com/Press+Releases/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html Fri, 19 Sep 2025 16:15:00 -0400 MDMA MDXXF http://www.streetinsider.com/Press+Releases/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html <p align="justify">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary short form base shelf prospectus (the “<strong>Prospectus</strong>”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when needed, during the 25-month period that the Prospectus, once made final, remains effective (the “<strong>Effective Period</strong>”). A copy of the http://www.streetinsider.com/Press+Releases/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html Fri, 19 Sep 2025 16:15:00 -0400 MDMA MDXXF http://www.streetinsider.com/Globe+Newswire/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html <p align="justify">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary short form base shelf prospectus (the “<strong>Prospectus</strong>”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when needed, during the 25-month period that the Prospectus, once made final, remains effective (the “<strong>Effective Period</strong>”). A copy of the http://www.streetinsider.com/Globe+Newswire/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html Fri, 19 Sep 2025 16:15:00 -0400 MDMA MDXXF http://www.streetinsider.com/Globe+Newswire/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html <p align="justify">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary short form base shelf prospectus (the “<strong>Prospectus</strong>”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when needed, during the 25-month period that the Prospectus, once made final, remains effective (the “<strong>Effective Period</strong>”). A copy of the http://www.streetinsider.com/Globe+Newswire/PharmAla+Files+Amended+and+Restated+Preliminary+Base+Shelf+Prospectus/25355724.html Fri, 19 Sep 2025 16:15:00 -0400 MDMA MDXXF http://www.streetinsider.com/Press+Releases/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html <p align="left">TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025.</p> <p align="left">“With the full onboarding of our distribution facility, PharmAla is now in a position to service clinical trial clients in the US rapidly, and without the need for additional import http://www.streetinsider.com/Press+Releases/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html Mon, 08 Sep 2025 16:05:00 -0400 MDMA MDXXF http://www.streetinsider.com/Press+Releases/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html <p align="left">TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025.</p> <p align="left">“With the full onboarding of our distribution facility, PharmAla is now in a position to service clinical trial clients in the US rapidly, and without the need for additional import http://www.streetinsider.com/Press+Releases/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html Mon, 08 Sep 2025 16:05:00 -0400 MDMA MDXXF http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html <p align="left">TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025.</p> <p align="left">“With the full onboarding of our distribution facility, PharmAla is now in a position to service clinical trial clients in the US rapidly, and without the need for additional import http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html Mon, 08 Sep 2025 16:05:00 -0400 MDMA MDXXF http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html <p align="left">TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025.</p> <p align="left">“With the full onboarding of our distribution facility, PharmAla is now in a position to service clinical trial clients in the US rapidly, and without the need for additional import http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+Import+of+LaNeo+MDMA+for+US+Distribution/25308950.html Mon, 08 Sep 2025 16:05:00 -0400 MDMA MDXXF http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Press+Releases/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html <p align="left">TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. (“<strong>PharmAla Australia</strong>”), a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.</p> <p>“As many know, Australia continues to be a thriving market for biotech development. We believe that our familiarity with the market – our relationships and our experience http://www.streetinsider.com/Globe+Newswire/PharmAla+Incorporates+Australian+Entity+for+Clinical+Research/25289629.html Wed, 03 Sep 2025 09:20:00 -0400 A.10269967 A.60012013 MDMA MDXXF O.54379156 http://www.streetinsider.com/Press+Releases/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html <p align="justify">TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company’s LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”).</p> <p align="justify">“We believe that this delivery sets a precedent in terms of the innovative terms agreed-to with Merhavim – terms that allows researchers to explore http://www.streetinsider.com/Press+Releases/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html Thu, 07 Aug 2025 08:55:00 -0400 MDMA MDXXF http://www.streetinsider.com/Press+Releases/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html <p align="justify">TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company’s LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”).</p> <p align="justify">“We believe that this delivery sets a precedent in terms of the innovative terms agreed-to with Merhavim – terms that allows researchers to explore http://www.streetinsider.com/Press+Releases/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html Thu, 07 Aug 2025 08:55:00 -0400 MDMA MDXXF http://www.streetinsider.com/Globe+Newswire/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html <p align="justify">TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company’s LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”).</p> <p align="justify">“We believe that this delivery sets a precedent in terms of the innovative terms agreed-to with Merhavim – terms that allows researchers to explore http://www.streetinsider.com/Globe+Newswire/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html Thu, 07 Aug 2025 08:55:00 -0400 MDMA MDXXF http://www.streetinsider.com/Globe+Newswire/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html <p align="justify">TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company’s LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”).</p> <p align="justify">“We believe that this delivery sets a precedent in terms of the innovative terms agreed-to with Merhavim – terms that allows researchers to explore http://www.streetinsider.com/Globe+Newswire/PharmAla+Delivers+MDMA+to+Merhavim+Mental+Health+Centre+Clinical+Trial+in+Exchange+for+Full+Data+License/25163998.html Thu, 07 Aug 2025 08:55:00 -0400 MDMA MDXXF http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements/25101250.html <p align="justify">TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D3qZuxGl5kQe2LO30q6Km6Qv2hDGJiaZskIT247WsL-_9fKSTtSieFcFbjoP9WT3eMBli5XYl7xf9eZtbgs9RQ==" http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements/25101250.html Fri, 25 Jul 2025 17:08:00 -0400 A.17150087 MDMA MDXXF O.49223070 http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements/25101250.html <p align="justify">TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D3qZuxGl5kQe2LO30q6Km6Qv2hDGJiaZskIT247WsL-_9fKSTtSieFcFbjoP9WT3eMBli5XYl7xf9eZtbgs9RQ==" http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements/25101250.html Fri, 25 Jul 2025 17:08:00 -0400 A.17150087 MDMA MDXXF O.49223070 http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements/25101250.html <p align="justify">TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D3qZuxGl5kQe2LO30q6Km6Qv2hDGJiaZskIT247WsL-_9fKSTtSieFcFbjoP9WT3eMBli5XYl7xf9eZtbgs9RQ==" http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements/25101250.html Fri, 25 Jul 2025 17:08:00 -0400 A.17150087 MDMA MDXXF O.49223070